Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 8.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 30,381 shares of the company’s stock after selling 2,793 shares during the period. Principal Financial Group Inc.’s holdings in Evolus were worth $492,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC boosted its position in Evolus by 9.9% in the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock valued at $162,000 after buying an additional 1,035 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Evolus by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after acquiring an additional 739 shares in the last quarter. Zimmer Partners LP purchased a new position in Evolus in the first quarter valued at about $4,200,000. Finally, Assenagon Asset Management S.A. grew its stake in Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after purchasing an additional 930,566 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insiders Place Their Bets

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 6.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 2.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EOLS shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Friday, September 13th. Barclays boosted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Price Performance

NASDAQ:EOLS opened at $12.60 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The business’s 50-day moving average price is $15.59 and its 200 day moving average price is $13.87. Evolus, Inc. has a 52-week low of $9.29 and a 52-week high of $17.82. The firm has a market cap of $797.83 million, a P/E ratio of -13.85 and a beta of 1.31.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.